Spa70

HepG2 cells (Cat#HB-8065) and HEK293 cells (Cat#CRL-11268) were purchased from ATCC. Huh7
cells were purchased from the Japanese Cancer Research Resources Bank (Cat#JCRB0403). All
cell lines were cultured in Dulbecco’s minimum essential medium (DMEM) (Thermo
Fisher Scientific), containing 4.5 g/L glucose and supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin and 1% non-essential amino acids (Thermo Fisher
Scientific).
Dexamethasone (500 nM), cortisol (500 nM), prednisolone (500 nM), GW4064 (5 μM),
GSK2033 (100 nM), 22(S)-hydroxycholesterol (10 μM) and RU486 (5 μM) were
purchased from Sigma-Aldrich. SPA70 (10 μM) was purchased from Axon Medchem
(Groningen, Netherlands). For all cell treatments, HEK293, HepG2 and Huh7 cells were
cultured in serum-free and phenol red-free media containing 4.5g/L glucose and
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% non-essential
amino acids.

Clotrimazole, ketoconazole, rifampicin, rifaximin, SR12813, and simvastatin were purchased from Sigma-Aldrich. SPA70 was obtained from Axon Medchem. Oligonucleotides were commercially synthesized by Macrogen. Restriction enzymes were purchased from New England Biolabs. All other reagents were obtained from Fujifilm Wako Pure Chemical or Sigma-Aldrich, unless otherwise indicated.